Ebos Group Ltd
EBO: XNZE (NZL)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|.b | LOCK|#R#Q | LOCK|kGf%hsk! |
Ebos Group Earnings: Disappointing Outlook as Costs Step Up
Ebos grew underlying fiscal 2025 EBITDA by 8%, with 18% sales growth in higher-margin medical technology. However, fiscal 2026 guidance implies just 5% organic EBITDA growth due to higher costs and softness in discretionary pet products. Shares reacted negatively, down 15%.
